Olaparib-durvalumab regimen prolongs PFS for certain women with advanced ovarian cancer
June 3, 2023 7:02 amKey takeaways:
- Researchers reported statistically significant improvement in median PFS with the combination added to standard of care in non-BRCA-mutated disease.
- The relative contribution of durvalumab requires further study.
CHICAGO — First-line chemotherapy plus bevacizumab and durvalumab … Read more